Exhibit 10.14
AMENDED AND RESTATED
CONSULTING AGREEMENT
BETWEEN ▇▇▇ ▇. ▇▇▇▇, M.D. AND
HYPERTENSION DIAGNOSTICS, INC.
This Agreement is entered into as of this 31st day of August, 1998, by
and between Hypertension Diagnostics, Inc., a Minnesota corporation (the
"COMPANY"), and ▇▇▇ ▇. ▇▇▇▇, M.D.
("CONSULTANT").
WHEREAS, the Company and Consultant previously entered into a
Consulting Agreement dated October 30, 1995 (the "1995 CONSULTING AGREEMENT");
and
WHEREAS, the Company desires to amend and restate the 1995 Consulting
Agreement to reflect the expanded nature and scope of consulting services to be
provided to the Company by Consultant, in accordance with the terms and
conditions set forth in this Agreement; and
WHEREAS, Consultant wishes to be engaged by the Company on such terms
and conditions.
NOW, THEREFORE, in consideration of the mutual promises and other good
and valuable consideration set forth herein, the parties hereby agree as
follows:
A. SUPERCEDES PRIOR AGREEMENTS. This agreement contains the entire
agreement of the parties relating to the engagement of Consultant by the Company
and the ancillary matters discussed herein and supersedes the 1995 Consulting
Agreement and all other prior agreements and understandings with respect to such
matters, and the parties hereto have made no agreements, representations or
warranties relating to such employment or ancillary matters which are not set
forth within.
B. TERM. The initial term of this Agreement (the "TERM") shall commence
on the date hereof and continue until August 31, 2001, unless terminated sooner
as provided below. In no event shall either party have any obligation to extend
or renew this Agreement following the end of the initial term hereunder. Without
limiting the generality of the foregoing, Consultant specifically acknowledges
that the Company has made no representations or promises to Consultant regarding
any services to be performed following the termination of this Agreement.
C. SERVICES. During the Term of this Agreement, Consultant shall serve
the Company in the following positions and/or capacities and shall perform such
duties as are reasonably consistent with such positions as the Board of
Directors shall assign to him from time to time:
1. CHIEF CLINICAL CONSULTANT (MEDICAL DIRECTOR). Consultant
shall be responsible for advising the Company on all medical and
clinical matters relating to the development and marketing of Company
products; analyzing cardiovascular industry trends and
alternative/competitive technologies; reviewing company informational
and promotional
brochures; advising the Company regarding strategic positioning of
technology; reviewing and advising the Company on the value of
scientific proposals submitted by outside researchers; advising the
Company on key medical issues/research findings; advising the Company
with respect to product development issues; authoring and publishing
compliance research data; serving as a medical/clinical reference to
customers; advising the Company regarding FDA matters and clinical
trials; hosting/chairing Company sponsored symposiums on arterial
compliance; and conducting Company sponsored research.
2. CHAIRMAN OF THE SCIENTIFIC AND CLINICAL ADVISORY BOARD.
Consultant shall be responsible for organizing, chairing and leading
the Company's Scientific and Clinical Advisory Board (the "ADVISORY
BOARD") with regard to discussions on scientific, technological and
physiological topics relating to use of the HDI/PULSEWAVETM
CardioVascular Profiling technology. Meetings of the Advisory Board
shall be held once or twice annually. Since members of the Advisory
Board will also be conducting research on behalf of the Company,
Consultant shall work with members to develop and review research study
protocols, and assist with study implementation, data analysis,
manuscript drafting and publication.
3. PUBLIC RELATIONS/INVESTOR RELATIONS SUPPORT. Consultant
shall assist the Company in making presentations to investors regarding
the clinical merit of the Company's technologies; participate in
shareholder meetings; assist in the development and execution of
investor relations/public relations strategies; serve as a clinical
spokesperson to the media on behalf of the Company; make public
presentations on behalf of the Company; and make scientific
presentations at medical conferences.
4. SALES/MARKETING SUPPORT. Consultant shall assist the
Company in customer sales/marketing presentations, customer contacts,
customer needs analysis, customer references, customer site visits,
convention/exhibition support, analysis of customer profiles,
convention/conference presentations, referral source for customer
contacts, analysis of customer data/trends, and review of Company
marketing tools and strategies.
5. OTHER DUTIES. Consultant shall provide other services as
requested by the Company regarding the research, clinical presentation,
marketing and sales of the Company's products.
D. COMPENSATION AND EXPENSES.
1. COMPENSATION--STOCK OPTION GRANT. As compensation for all
services to be rendered by Consultant under this Agreement during the
full term of this Agreement, the Company grant shall Consultant a
nonqualified option to purchase up to 100,000 shares of the common
stock of the Company at a price of $3.656 per share, in the form
attached hereto and labeled as EXHIBIT A.
2
2. EXPENSES. The Company shall pay or reimburse Consultant for
all reasonable and necessary out-of-pocket expenses incurred by him in
the performance of his duties under this Agreement, subject to
compliance by Consultant with the Company's policies for expense
reimbursements.
E. CONFIDENTIALITY.
1. Consultant shall keep confidential and not disclose to
anyone or use, either during the Term of this Agreement or thereafter,
any confidential information of the Company, except as required by this
Agreement, or as authorized in writing by the Company. Confidential
information means any information which derives independent economic
value from not being generally known or readily ascertainable by proper
means ("Confidential Information"). Examples of Confidential
Information which is not to be disclosed or used includes, but is not
limited to: existing or contemplated products, services, processes,
techniques, know-how, data, customer identity, customer documents,
projects, customer lists, formulas, products, data devices, study
results, software, hardware, firmware and any other of the Company or
Customer information designated as confidential.
2. Consultant agrees not to remove any Confidential
Information from the Company's premises, except as necessary in the
ordinary course of conducting business for and subject to the prior
approval of the Company. Upon cancellation of this Agreement,
Consultant shall immediately return all documents and Confidential
Information, and all other tangible property of the Company to the
Company.
F. COVENANT NOT TO COMPETE. Consultant expressly acknowledges that he
is entering into this covenant not to compete so as to protect the business and
goodwill of the Company from competition in the event of a termination of the
consultancy relationship and Consultant further acknowledges the reasonableness
of the restriction imposed herein. Accordingly, Consultant warrants and agrees
that:
1. Consultant will inform any new employer, before accepting
employment, of the existence of this Agreement and give such new
employer a copy of this Section F, Covenant Not to Compete.
2. Consultant will not, for a period beginning from the date
of this Agreement and for twelve (12) months after the termination
thereof, sell to, solicit, serve, or attempt to sell to, solicit, or
serve any customer, client or account or any prospective customer,
client or account of the Company; PROVIDED, HOWEVER, that the foregoing
limitation shall only apply to sales, solicitations, services or
attempts to do any of the foregoing which involve a Competing Product.
A "customer, client or an account" is any person, firm or entity to
whom or to which the Company furnished any services, materials, or
products at any time during the term of this Agreement. A "prospective
customer, client or account" is one which, during Employee's
consultancy relationship with the Company, is solicited, successfully
or
3
unsuccessfully, to become a customer, client or account of the Company.
As used herein, a "Competing Product" is a product similar to or in
competition with any product, or planned product, of the Company as of
the date this Agreement is terminated.
3. Consultant will not, from a period beginning with the date
of this Agreement and for twelve (12) months after the termination
thereof, cause or attempt to cause any customer, client or account or
any prospective customer, client or account, to divert, terminate,
limit or in any manner modify or fail to enter into any actual or
potential business relationship with the Company.
4. Consultant will not, for a period beginning with the date
of this Agreement and for twelve (12) months after the termination
thereof, divert, solicit, or employ, or attempt to divert, solicit, or
employ any employees of the Company.
5. Consultant shall not, directly or indirectly, from a period
beginning from the date of this Agreement and for twelve (12) months
after the termination thereof, engage in competition with the Company
in any manner or capacity (e.g., as an advisor, principal, agent,
partner, officer, director, stockholder, employee, member of any
association, or otherwise) for a competitor of the Company.
6. The obligations of Consultant under this Section F shall
apply to any geographic area in which the Company: (i) has engaged in
business during the term of this Agreement through production,
promotional, sales or marketing activity, or otherwise, (ii) has
otherwise established the Company's goodwill, business reputation or
any customer or supplier relations, or (iii) has been directly involved
in the expansion of the Company's business and development of the
Company's customer base.
G. INVENTIONS/ASSIGNMENT.
1. Consultant acknowledges and agrees that the Company is and
shall remain the owner of all materials, information, copyrightable
information, trademarks, or other proprietary information
(collectively, the "Proprietary Information") developed by Consultant
as a function of his relationship with the Company either prior to or
after commencement of the relationship described hereunder and that any
such Proprietary Information shall be treated as "works for hire" under
applicable law.
2. Both during the term of this Agreement and thereafter,
Consultant shall treat all Proprietary Information and all other
information that he has obtained about the Company's operation as
confidential. Without the prior written consent of the Company,
Consultant shall not copy or reproduce the Proprietary Information
except to the extent necessary to perform the services to be provided
under this Agreement. Upon termination of this Agreement, Consultant
shall promptly turn over to the Company all copies of Proprietary
Information and all other materials (including work in process)
developed in the
4
course of its consulting for the Company hereunder. The obligations of
Consultant under this paragraph shall survive termination of this
Agreement.
3. This Section G does not apply to an Invention for which no
equipment, supplies, facility or trade secret information of the
Company was used and which was developed entirely on Consultant's own
time, and (1) which does not relate (a) directly to the business of the
Company or (b) to the Company's actual or demonstrably anticipated
research or development, or (2) which does not result from any work
performed by Consultant for the Company.
H. TERMINATION. Either party may terminate this Agreement at any time,
for any reason, by providing 30 days written notice of such termination to the
other party. Notwithstanding the foregoing, the confidentiality obligations
relating to Proprietary Information and other responsibilities of Consultant
hereunder and the obligation of the Company to make payment to Consultant as
provided herein for work performed prior to the termination of this Agreement,
shall survive the termination of this Agreement.
I. LEGAL STATUS OF CONTRACTOR.
1. Consultant is an independent contractor subject to the
terms and conditions of this Agreement. Consultant will not make any
representation, either express or implied, to the contrary.
2. Any and all income tax returns filed by Consultant with
either the federal or state governments shall be prepared in accordance
with the terms of this Agreement; such returns shall indicate that all
income Consultant receives as a result of this Agreement is income
earned as an independent contractor and not as an employee of the
Company.
3. Because Consultant is not an employee of the Company and is
expressly an independent contractor under this Agreement, the Company
will not provide any employee benefits or withhold monies from
Consultant's compensation for federal or state income tax purposes.
Furthermore, the Company will not make any payment or contribution in
Consultant's name or on his behalf for purposes of social security,
unemployment compensation, workers' compensation, or for any other
similar purpose.
J. INDEMNIFICATION.
1. The Company shall defend, indemnify and hold Consultant
harmless from and against any and all claims, liabilities, damages,
costs and expense (including reasonable attorneys' fees) ("the Claims")
which Consultant may at any time incur arising out of, related to, or
in connection with Consultant's performance of his duties hereunder,
except where such Claims arise in whole or in part from Consultant's
negligence or misconduct.
5
2. Consultant shall defend, indemnify and hold the Company,
and its officers, directors, employees, agents, and other
representatives, harmless from and against any Claims which the Company
may at any time incur arising out of, related to, or in connection with
Consultant's negligence or misconduct in the performance of his duties
hereunder.
K. NOTICE. Any notice or other communication required or permitted
pursuant to the terms of this Agreement shall be in writing and shall be deemed
to have been duly given or served if delivered, in person or deposited in the
United States mail, postage prepaid, for mailing by certified or registered
mail, return receipt requested or of telegram, by prepaid telegram, telex,
facsimile, or telecopier, and addressed, to a party to this Agreement, to the
address set forth below:
If to Company: Hypertension Diagnostics, Inc.
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
ATTN: President
Facsimile No. (▇▇▇) ▇▇▇-▇▇▇▇
If to Consultant: ▇▇. ▇▇▇ ▇. ▇▇▇▇
Professor of Medicine
University of Minnesota Medical School
Cardiovascular Division, Box 508
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇.▇.
▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Facsimile No. (▇▇▇) ▇▇▇-▇▇▇▇
L. SETTLEMENT OF DISPUTES.
1. ARBITRATION. Except as provided in section L.2., any claims
or disputes of any nature between the Company and Consultant arising
from or related to the performance, breach, termination, expiration,
application, or meaning of this Agreement or any matter relating to
Consultant's consultancy relationship and the termination of that
relationship by the Company shall be resolved exclusively by
arbitration in Minneapolis, Minnesota, in accordance with the
applicable rules then obtaining of the American Arbitration
Association. The arbitrators shall be required to provide a written
analysis of their decision. The fees of the arbitrator(s) and other
costs incurred by Consultant and the Company in connection with such
arbitration shall be paid by the party who is unsuccessful in such
arbitration.
The decision of the Arbitrator(s) shall be final and binding
upon both parties. Judgment of the award rendered by the arbitrator(s)
may be entered in any court having jurisdiction thereof. In the event
of submission of any dispute to arbitration, each party shall,
6
not later than thirty (30) days prior to the date set for hearing,
provide to the other party and to the arbitrator(s) a copy of all
exhibits upon which the party intends to rely at the hearing and a list
of all persons each party intends to call at the hearing.
2. RESOLUTION OF CERTAIN CLAIMS - INJUNCTIVE RELIEF. Section
L.1. shall have no application to claims by the Company asserting a
violation of sections E, F or G or seeking to enforce, by injunction or
otherwise, the terms of either sections E, F or G. Such claims may be
maintained by the Company in a lawsuit subject to the terms of section
L.3. Consultant agrees that, in addition to, but not to the exclusion
of any other available remedy, the Company shall have the right to
enforce the provisions of sections E, F or G by applying for and
obtaining temporary and permanent restraining orders or injunctions
from a court of competent jurisdiction without the necessity of filing
a bond therefor, and the Company shall be entitled to recover from
Consultant its reasonable attorneys' fees and costs in enforcing the
provisions of sections E, F or G.
3. VENUE. Any action at law, suit in equity, or judicial
proceeding arising directly, indirectly, or otherwise in connection
with, out of, related to or from this Agreement or any provision
hereof, shall be litigated only in the courts of the state of
Minnesota, County of ▇▇▇▇▇▇ or Dakota, or the ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇,
▇▇▇▇▇▇▇▇ of Minnesota, Fourth Division. Consultant waives any right
Consultant may have to transfer or change the venue of any litigation
brought against Consultant by the Company. Consultant also waives any
claim of inconvenient forum.
M. MISCELLANEOUS.
1. GOVERNING LAW. This agreement is made under and shall be
governed by and construed in accordance with the laws of the state of
Minnesota other than its law dealing with conflicts of law.
2. AMENDMENTS. No amendment or modification of this Agreement
shall be deemed effective unless made in writing and signed by both
Consultant and the Company.
3. NO WAIVER. No term or condition of this Agreement shall be
deemed to have been waived, nor shall there by any estoppel to enforce
any provision of this Agreement, except by a statement in writing
signed by the party against whom enforcement of the waiver or estoppel
is sought. Any written waiver shall not be deemed a continuing waiver
unless specifically stated, shall operate only as to the specific term
or condition waived and shall not constitute a waiver of such term or
condition for the future or as to any act other than that specifically
waived.
4. SEVERABILITY. To the extent any provision of this Agreement
shall be invalid or unenforceable, it shall be considered deleted
herefrom and the remainder of such provision and of this Agreement
shall be unaffected and shall continue in full force and effect. In
7
furtherance and not in limitation of the foregoing, should the duration
or geographical extent of, or business activities covered by, any
provision of this Agreement be in excess of that which is valid and
enforceable under applicable law, then such provision shall be
construed to cover only that duration, geographical extent or business
activities which may be valid and enforceable under applicable law.
Consultant acknowledges the uncertainty of the law in this respect and
expressly stipulates that this Agreement be given the construction
which renders its provisions valid and enforceable to the maximum
extent (not exceeding its express terms possible under applicable law).
5. ASSIGNMENT. This Agreement shall not be assignable, in
whole or in part, by either party without the written consent of the
other party.
6. COUNTERPARTS. This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original, but all of
which shall constitute one and the same instrument.
7. CAPTIONS AND HEADINGS. The captions and section headings
used in this Agreement are for convenience of reference only, and shall
not affect the construction or interpretation of this Agreement or any
of the provisions hereof.
IN WITNESS WHEREOF, the undersigned have executed this Agreement
effective as of the day and year first above written.
HYPERTENSION DIAGNOSTICS, INC.
By /S/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ /S/ ▇▇▇ ▇. ▇▇▇▇, M.D.
----------------------------- -----------------------------
▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, President ▇▇▇ ▇. ▇▇▇▇, M.D., Consultant
8
EXHIBIT A
STOCK OPTION AGREEMENT
9
HYPERTENSION DIAGNOSTICS, INC.
STOCK OPTION AGREEMENT
THIS AGREEMENT is entered as of August 31, 1998 by and between
Hypertension Diagnostics, Inc., a Minnesota corporation (the "COMPANY") and ▇▇▇
▇. ▇▇▇▇, M.D. (the "PARTICIPANT").
WHEREAS, the Company maintains the 1998 Stock Option Plan (the "1998
Plan"), which is incorporated into and forms a part of this Agreement, and the
Participant has been selected by the individuals administering the 1998 Plan
(the "Committee") to receive a Nonqualified Stock Option under the 1998 Plan;
NOW, THEREFORE, IT IS AGREED, by and between the Company and the
Participant, as follows:
1. TERMS OF OPTION. The following terms used in this Agreement shall
have the following meanings.
a. The "Participant" is ▇▇▇ ▇. ▇▇▇▇, M.D.
b. The "Date of Grant" is August 31, 1998.
c. The number of "Covered Shares" shall be 100,000 shares of
Common Stock.
d. The "Exercise Price" is $3.656.
e. The "Expiration Date" is August 30, 2008.
2. GRANT OF OPTION. The Company hereby grants to the Participant an
option (the "OPTION") to purchase the number of Covered Shares of Common Stock
at the Exercise Price per share as set forth in paragraph 1, subject to all of
the terms and conditions of the 1998 Plan. This Option is not intended to
constitute an Incentive Stock Option within the meaning of Section 422 of the
Internal Revenue Code of 1986, as amended (the "CODE").
3. EXERCISE OF OPTION.
a. DATE OF EXERCISE. The Option shall become
exercisable according to the following schedule.
As of the Date of Grant and each The Option shall become exercisable
succeeding anniversary of the Date of with respect to the following percentage
Grant: of the Covered Shares:
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
August 31, 1998 33,334 Shares (33.34%)
--------------------------------------------------------------------------------
August 31, 1999 33,333 Shares (33.33%)
--------------------------------------------------------------------------------
August 31, 2000 33,333 Shares (33.33%)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Exercisability under this schedule is cumulative. After the Option
becomes exercisable with respect to any portion of the Covered Shares,
it shall continue to be exercisable with respect to that portion of the
Covered Shares until the Option expires. The Option shall not be
exercisable on or after the Expiration Date as set forth in paragraph 1.
b. LIMITATIONS ON EXERCISE. The Covered Shares shall not be
issued unless the exercise of the Option and the issuance of such
Covered Shares shall comply with all applicable provisions of the law
and the applicable requirements of any stock exchange or Nasdaq. As a
condition to the exercise of all or any portion of the Option, the
Company may require the person exercising such Option to represent and
warrant at the time of any such exercise that the Covered Shares are
being purchased only for investment and without any present intention
to sell or distribute the Covered Shares.
4. TERMINATION.
a. TERMINATION FOR ANY REASON EXCEPT DEATH OR DISABILITY. If
Participant's consultancy relationship with the Company and all Related
Companies is terminated for any reason other than for death or
disability, the Option, to the extent that it would have been
exercisable by the Participant on the Date of Termination, may be
exercised by Participant no later than the Expiration Date.
b. TERMINATION BY REASON OF DEATH OR DISABILITY. If
Participant's consultancy relationship with the Company and all Related
Companies is terminated due to death or disability (within the meaning
of Section 22(e)(3) of the Code) of the Participant, the Option, to the
extent that it is exercisable on the Date of Termination, may be
exercised by Participant (or Participant's estate or legal
representative) no later than one year after such Date of Termination;
provided, however, the Option shall not be exercisable after the
Expiration Date.
▇. ▇▇▇▇ OF TERMINATION. For purposes of this Agreement, the
Participant's "Date of Termination" shall be the first day occurring on
or after the Date of Grant on which the Participant's consultancy
relationship with the Company and all Related Companies terminates for
any reason.
5. METHOD OF EXERCISE. The Option may be exercised in whole or in part
by delivering a written notice (in such form as may be approved by the
Committee) to the Secretary of the
-2-
Company at its corporate headquarters prior to the Expiration Date. Such written
notice shall be accompanied by payment of the Exercise Price for such shares of
Common Stock being purchased. Payment shall be by cash or by check payable to
the Company. Except as otherwise provided by the Committee before the Option is
exercised: (i) all or a portion of the Exercise Price may be paid by the
Participant by delivery of shares of Common Stock acceptable to the Company and
having an aggregate Fair Market Value (valued as of the date of exercise) that
is equal to the amount of cash that would otherwise be required; and (ii) the
Participant may pay the Exercise Price by authorizing a third party to sell
shares of Common Stock (or a sufficient portion of the shares) acquired upon
exercise of the Option and remit to the Company a sufficient portion of the sale
proceeds to pay the entire Exercise Price and any tax withholding resulting from
such exercise.
6. TAX WITHHOLDING. All distributions under this Agreement are subject
to withholding of all applicable taxes. At the election of the Participant, and
subject to such rules as may be established by the Committee, such withholding
obligations may be satisfied through the surrender of shares of Common Stock
which the Participant already owns, or to which the Participant is otherwise
entitled under the 1998 Plan.
7. NOTICE OF DISQUALIFYING DISPOSITION OF SHARES. If the Option is an
Incentive Stock Option and if the Participant sells or otherwise disposes of any
of the shares acquired pursuant to the Option on or before two years from the
Date of Grant or one year following the exercise of the Option, the Participant
shall immediately notify the Company in writing of such disposition. The Company
shall have the right to require the Participant to remit to the Company an
amount sufficient to satisfy any withholding requirements.
8. NONTRANSFERABILITY OF OPTION. The Option is not transferable in any
manner other than by will or by the laws of descent and distribution and may be
exercised during the Participant's life only by the Participant. The terms of
the Option shall be binding upon the executors, administrators, heirs,
successors and assigns of the Participant.
9. ADMINISTRATION. The authority to control and manage the operation
and administration of this Agreement shall be vested in the Committee, and the
Committee shall have all powers with respect to this Agreement as it has with
respect to the 1998 Plan. Any interpretation of this Agreement by the Committee
and any decision made by it with respect to this Agreement is final and binding.
10. PLAN DEFINITIONS. Notwithstanding anything in this Agreement to the
contrary, the terms of this Agreement are subject to the terms of the 1998 Plan,
a copy of which may be obtained by the Participant from the Secretary of the
Company.
11. NO EFFECT ON TERMS OF EMPLOYMENT. Nothing in this Agreement shall
confer on the Participant any right with respect to continuation of a consulting
relationship with the Company or any Related Company, or limit the right of the
Company or any Related Company to terminate the Participant's consulting
relationship at any time, with or without cause.
12. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon, and
inure to the benefit of, the Company and its successor and assigns, and upon any
person acquiring, whether by
-3-
merger, consolidation, purchase of assets or otherwise, all or substantially all
of the Company's business and assets.
13. GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of Minnesota.
14. PARTICIPANT ACKNOWLEDGMENT. Participant hereby acknowledges receipt
of a copy of the 1998 Plan. Participant has read and understands the terms and
provisions thereof, and accepts the Option subject to all the terms and
conditions of the 1998 Plan and this Agreement.
IN WITNESS WHEREOF, the Participant has executed this Agreement, and
the Company has caused this Agreement to be executed in its name and on its
behalf, all as of the date of this Agreement.
PARTICIPANT HYPERTENSION DIAGNOSTICS, INC.
/S/ ▇▇▇ ▇. ▇▇▇▇, M.D. By: /S/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------------- -----------------------------
Signature ▇▇▇▇. ▇. ▇▇▇▇▇▇▇▇
Its: President
▇▇▇ ▇. ▇▇▇▇, M.D.
-------------------------------------
Print Name
-4-
HYPERTENSION DIAGNOSTICS, INC.
1998 STOCK OPTION PLAN
NOTICE OF STOCK OPTION EXERCISE
Optionee Name:
------------------------------------------------------------------
Social Security Number:
---------------------------------------------------------
Address:
------------------------------------------------------------------------
1. I hereby elect to purchase _______ shares of common stock at an
exercise price per share of $__________ pursuant to the Stock Option
Agreement dated August 31, 1998 and the 1998 Stock Option Plan (the
"1998 Plan").
2. The shares should be issued in the name(s) of:_______________________
____________________________________________________________________ .
3. I hereby deliver payment of the purchase price as follows (check
appropriate box):
/ / in cash or check in the amount of $___________.
/ / by delivering shares of common stock having a Fair Market
Value (as defined in the 1998 Plan) on the date of exercise
equal to the purchase price.
/ / through the simultaneous sale through a broker of shares of
common stock acquired upon the exercise of the option (i.e., a
cashless exercise).
/ / a combination of cash and shares of common stock together
having a Fair Market Value on the date of exercise equal to
the purchase price.
IF PREVIOUSLY-ACQUIRED COMMON STOCK IS USED TO PAY THE PURCHASE PRICE,
THE COMMON STOCK MUST BE FREELY TRANSFERABLE AND HELD BY THE OPTIONEE
FOR AT LEAST SIX MONTHS.
4. I have received a copy of the complete 1998 Plan and agree to be bound
by the terms and conditions of the 1998 Plan.
5. I understand that my exercise of the option and sale of the shares
acquired upon exercise may have certain adverse tax consequences and
that I should consult with my own personal tax advisor concerning the
possible tax consequences.
Dated:
--------------------------- --------------------------------
Signature of Optionee